Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients.

EPMA J · 2010 · PMC3405335 · PMID 23199086

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In 465 patients with locally advanced hormone receptor-positive breast cancer enrolled in the Eastern Cooperative Oncology Group (ECOG) E2197-trial treated with doxorubicin plus cyclophosphamide or docetaxel, plus tamoxifen if ER-positive, the RS was a highly significant predictor of recurrence in both lymph-node negative and lymph-node positive disease [ 82 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.